Lantheus Holdings, Inc. (NASDAQ:LNTH) CFO Robert J. Jr. Marshall Sells 10,000 Shares

Lantheus Holdings, Inc. (NASDAQ:LNTH) CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Lantheus Price Performance

LNTH stock traded up $1.06 during midday trading on Wednesday, reaching $103.28. The company had a trading volume of 505,639 shares, compared to its average volume of 937,125. Lantheus Holdings, Inc. has a 1-year low of $56.52 and a 1-year high of $126.89. The stock has a 50 day moving average price of $92.54 and a 200-day moving average price of $96.68. The company has a market capitalization of $7.07 billion, a price-to-earnings ratio of 17.18 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Institutional Investors Weigh In On Lantheus

A number of hedge funds have recently made changes to their positions in LNTH. Geode Capital Management LLC boosted its position in Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after buying an additional 32,551 shares in the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in shares of Lantheus during the 3rd quarter valued at $25,955,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Lantheus by 47.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock valued at $1,041,000 after purchasing an additional 3,772 shares in the last quarter. Empirical Asset Management LLC acquired a new stake in shares of Lantheus during the fourth quarter valued at about $323,000. Finally, Focus Financial Network Inc. acquired a new stake in shares of Lantheus during the fourth quarter valued at about $292,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on LNTH shares. Truist Financial lifted their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. The Goldman Sachs Group assumed coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, JMP Securities restated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $132.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.